Introduction
Chemicals that are metabolized to reactive intermediates are important industrial and environmental carcinogens. The kidney proximal tubule epithelium is a target for these chemicals due to its high metabolism and ability to concentrate toxicants (Cronin and Henrich, 1995; Goldstein and Schnellmann, 1996) . Apoptosis contributes to kidney injury in vivo (Lieberthal and Levine, 1996; Edelstein et al., 1997) . Recently, we showed that caspase activation contributes to cell detachment prior to apoptosis of renal epithelial cells (van de Water et al., 1999) . However, apoptosis of kidney epithelial cells is not fully understood and may dier from other tissues and cell types (Trudel et al., 1997) . Moreover, the role of apoptosis vs necrosis in kidney injury due to environmental toxicants has not been addressed critically.
Apoptosis and necrosis are morphologically distinct. Apoptosis deletes cells under physiological or pathological conditions and is characterized by morphological changes such as chromatin condensation, nuclear or DNA fragmentation and formation of apoptotic bodies (Majno and Joris, 1995; Kerr et al., 1972) . Apoptotic bodies are phagocytized unless their number exceeds the phagocytic capacity whereupon they rupture in a process termed secondary necrosis (Majno and Joris, 1995; Kerr et al., 1972) . Apoptosis is positively and negatively regulated by oncogenes such as bcl-2, myc, p53 and Rb (Evan and Littlewood, 1998) . For example, prolonged c-myc expression sensitizes ®broblastic cells to apoptotic cell death (Evan and Littlewood, 1998; Packham and Cleveland, 1995) . Over expression of cmyc also causes apoptosis of renal epithelial cells in vivo (Trudel et al., 1997) and c-myc expression after nephrotoxicant exposure can be a pro-apoptotic signal (Zhan et al., 1997) .
By contrast, necrosis is an accidental form of death due to traumatic injury (Majno and Joris, 1995) . Necrotic cells swell and rupture releasing cellular contents that cause in¯ammation. Apoptotic cells shrink and detach from their neighbors; in culture they appear as¯oating apoptotic bodies while necrotic cells corpses can remain attached (Majno and Joris, 1995) . In addition, common markers of apoptosis (nucleosomal ladders formation, caspase activation and annexin V redistribution) are largely absent in necrotic cells (Bonfoco et al., 1995; Leist et al., 1997) . However, the two pathways may be linked, at least with respect to chemical toxicants, since chemicals may cause either necrosis, apoptosis, or both, depending on the concentration, cellular ATP content, reactive oxygen species and antioxidants (Bonfoco et al., 1995; Buttke and Sandstrom, 1994; Eguchi et al., 1997; McGowan et al., 1996; Leist et al., 1997; Zhan et al., 1997) .
Although the signals that cause apoptosis in kidney after chemical injury are not clear, aspartate-directed cysteine protease, i.e. caspases, are important in the execution phase of apoptosis in general (Cohen, 1997; Thornberry and Lazebnik, 1998) . Apoptotic signals activate procaspases in a protease cascade (Cohen, 1997; Thornberry and Lazebnik, 1998; Ashkenazi and Dixit, 1998; Green and Reed, 1998) . Ligation of CD95 by FasL or anti-Fas antibody activates procaspase-8, through a complex of proteins associated with the cytoplasmic tail of the receptor (Ashkenazi and Dixit, 1998) . More than a dozen cellular proteins are caspase substrates and cleavage of these proteins is believed to cause cell death (Cohen, 1997; Martin and Green, 1995) . Cathepsins may also participate in apoptosis downstream of caspase activation (Deiss et al., 1996; Guenette et al., 1994; Simboli-Campbell et al., 1997; Brunk et al., 1997; Moallem and Hales, 1995; Roberts et al., 1997) .
The Bcl-2 family of proteins also regulate apoptosis (Reed, 1994 (Reed, , 1997 Kroemer, 1997; Adams and Cory, 1998) . Bcl-2 is found predominately in the outer mitochondrial membrane but also in the endoplasmic reticulum and nuclear membranes (Reed, 1997) . Bcl-2, and homologous proteins, antagonize apoptosis by preventing calcium deregulation, formation of reactive oxygen species, and release of cytochrome C or apoptosis-inducing factor from mitochondria (Distelhorst et al., 1996; Jacobson, 1996; Susin et al., 1996; Yang et al., 1997; Zornig et al., 1995) . Bcl-2 also blocks caspase activation and may prevent necrotic cell death in some cells (Kane et al., 1995; Shimizu et al., 1996) indicating that the two pathways shares some common elements. Other bcl-2 family members have proapoptotic properties (Adams and Cory, 1998) .
Nephrotoxic cysteine conjugates metabolites are formed from halogenated alkenes such as tetrafluoroethylene, trichloroethylene, tetrachloroethylene and hexachlorobutadiene (Lock, 1989) and are a unique model to study kidney cell death. The mode of cell death, apoptosis vs necrosis, can be altered during conjugate treatment by adding antioxidants (van de Water et al., 1996; Zhan et al., 1997) . Minor structural modi®cations also provide a tool to segregate apoptotic signals, such as c-myc induction, from necrotic signaling (Zhan et al., 1997) . In previous studies, we focused on the role of cytoskeletal perturbations and loss of signaling through focal adhesions in DCVCinduced cell death (van de Water et al., 1996 (van de Water et al., , 1999 . Herein, we investigated the role of bcl-2 and caspase activation and cell death induced by nephrotoxic cysteine conjugates and another prototypical nephrotoxicant, cisplatin. We show that caspase activation by bcl-2 dependent and -independent pathways contributes to apoptosis in kidney epithelial cells. Moreover, cathepsins also contribute to apoptosis after DCVC treatment. The data provide new insights into the activation of protease cascades during apoptosis in renal epithelial cells and in cell death in general.
Results

Protease inhibitors block apoptosis in LLC-PK1 cells
We investigated the eect of a variety of protease inhibitors on apoptotic cell death in LLC-PK1 renal epithelial cells. Apoptosis was initiated by treating cells with 1.5 mM DCVC in the presence of 20 mM DPPD for 6 h, a time at which no cell death is detected. Cells were then returned to complete medium in the absence or presence of inhibitors of caspases (zVAD.fmk), cathepsins (zFA.fmk and E64) and nonspeci®c inhibitors (pepstatin A, TLCK, TPCK) for proteases with serine or cysteine residues at the active site ( Figure  1 ). Cell death was monitored 24 h after adding DCVC by assessing DNA fragmentation and LDH release. Both zVAD.fmk, which inhibits caspase-1 and caspase-3-like enzymes, and zFA.fmk, a cathepsin inhibitor, blocked cell death as determined by LDH release, but only zVAD.fmk prevented DNA ladder formation. Adding zVAD.fmk also blocked cell detachment, nuclear fragmentation, DNA ladder formation and cell death in a concentration dependent manner ( Figure  2 ) and over a range of DCVC concentrations ( Figure  3 ). At higher concentrations of DCVC, i.e. 2.0 ± 2.5 mM, DNA ladders are lost because apoptotic cells lose membrane integrity. Although DCVC causes a concentration-dependent increase in apoptosis, it is important to point out that the steep dose response curve ( Figure 3 ) causes interexperimental variation as may be noted in experiments described below (see Materials and methods for additional details). High density control cells, largely in the G0/G1 phase of the cell cycle, were used in all experiments ( Figure 4 ). Adding zVAD.fmk reduced the number of apoptotic cells from 66 to 12% after DCVC treatment ( Figure 4 ). However, zFA.fmk, the cathepsin inhibitor, did not reduce the percentage of cells detected in the subG0/G1 population after DCVC treatment, but did increase the¯uorescence intensity in the subG0/G1 population suggesting that cells treated with zFA.fmk after exposure to DCVC had a higher DNA content. Taken together, the data suggest that caspases are involved in DCVC-induced apoptosis. Although cathepsin inhibition did not block apoptosis, it delayed cell rupture and LDH release, accounting for the apparent decrease in cell death noted in Figure 1 , and the increase in DNA content of the apoptotic cells.
Signals for necrosis and apoptosis diverge upstream of protease activation
To further validate the association between apoptosis and caspase activation, we compared DCVC, which causes apoptosis, with TFEC, which does not (Zhan et al., 1997) . After treatment with DCVC, which is genotoxic (Vamvakas et al., 1989) , LLC-PK1 cells die by necrosis if antioxidants, i.e. DPPD, are absent but by apoptosis when DPPD is present to stabilize the plasma membrane (van de Water et al., 1996; Zhan et al., 1997) . TFEC, a¯uorinated analog of DCVC, is activated by the same kidney b-lyase, but kills LLC-PK1 cells exclusively by necrosis and not apoptosis (Zhan et al., 1997) . By exploiting the dierences between TFEC and DCVC we were able to discriminate between the two pathways within a single model of chemically-induced cell death. Figure 1 and returned to complete medium with DPPD in the presence or absence of 100 mM zVAD.fmk or 100 mM zFA.fmk for another 18 h. The DNA content (propidium iodide staining) in the combined cells population, i.e.¯oating plus trypsinized attached cells, was measured by¯ow cytometer. The ordinate indicates the cell counts and the abscissa is propidium iodide¯uorescence. In these con¯uent culture, 490% of the cells are in the G0/G1 phase. Percentages in the subG0/G1 population are shown in the upper right hand corner of each panel. The data are from an experiment representative of two (n=2) In the absence of DPPD, i.e. necrotic conditions, zVAD.fmk did not inhibit DCVC-induced cell death and caspase activity was detected only when cells underwent apoptosis, not necrosis (absence of DPPD) (Table 1) . However, with TFEC, DEVDase activity was not detected in the presence or absence of DPPD nor were other markers of apoptosis observed (data not shown). Thus, caspase activation occurred only when apoptosis was the predominant pathway for cell death. Furthermore, caspase activation does not occur simply because cell death is induced in the presence of DPPD but is speci®c for DCVC, the genotoxic nephrotoxic cysteine conjugates capable of inducing apoptosis. Finally, LDH release, due to apoptosis and secondary necrosis, is prevented by caspase inhibitors con®rming its use as a quantitative measure of apoptosis in conjunction with other markers.
To dierentiate further between necrotic and apoptotic cell death caused by DCVC, we determined if biochemical inhibitors of necrosis would block apoptosis. After DCVC treatment, oxidative stress, initiated by an increase of intracellular calcium, leads to mitochondrial dysfunction and loss of membrane integrity without the appearance of apoptotic morphology (Chen et al., 1990; van de Water et al., 1994) . Desferroxamine, an iron chelator, EGTA-AM, a calcium chelator, and ruthenium red, an inhibitor of the mitochondrial Ca 2+ -uniporter, all prevent necrotic cell death caused by DCVC (Chen et al., 1990; van de Water et al., 1994 ). Yet, none of these inhibitors had any eect on caspase-3 activity or DCVC-induced apoptosis (data not shown). Thus, caspase activation is either upstream or occurs independently of these events in DCVC-induced necrosis.
Proteolysis and activation of caspase-3 but not caspase-1 after DCVC treatment
The activation of a DEVDase and inhibition of apoptosis by zVAD.fmk suggested that a caspase-3-like proteases was activated during apoptosis. To con®rm this we measured the activity of caspase-1 and caspase-3 related proteases during apoptosis using Ac-YVAD.pNA and Ac-DEVD.pNA as substrates, respectively, and monitored cleavage of caspase-3 and PARP. Apoptosis was initiated by a 6 h treatment with DCVC in the presence of DPPD. At the end of the 6 h treatment, there was no increase in YVADase or DEVDase activity (Figure 5a ). However, after returning cells to complete medium, DEVDase activity increased coincident with an increase in DNA ladders, detachment and cell death (Figure 5a and data not shown; see (Zhan et al., 1997) . No YVADase Cells were treated with DCVC or TFEC in EBSS with or without DPPD, as indicated in the table, for 6 h and then allowed to recover in complete medium+DPPD with or without 100 mM zVAD.fmk present. Control cells received EBSS alone. Cell death was determined by LDH release 24 h after starting toxicant. In addition, caspase-3 activity was measured in cell lysates prepared 24 h after initiating toxicant treatment. The data are the means+the range of data from two separate experiments (n=2). Signi®cant dierences (P50.05) in cell death due to zVAD.fmk addition were determined for each treatment condition by comparing the two means using a one-tailed Student's t-test. When a signi®cant dierence was detected, the mean in the +zVAD column is marked with an asterisk. Signi®cant increases (P50.05) in caspase-3 activity were determined using a one way ANOVA followed by the StudentNewman-Keuls test for multiple comparisons; means marked with an asterisk were signi®cantly dierent from the control Figure 5 Induction of a Caspase-3 (like) activity. (a) LLC-PK1 cells were exposed to either EBSS or 1.5 mM DCVC with DPPD for 6 h and then returned to complete medium with DPPD. At various times after starting the DCVC treatment, the caspase-1 (Casp-1) and caspase-3 (Casp-3) activity were determined. The bars marked 18+zVAD indicates that zVAD.fmk was added to a lysate prepared from cells 18 h after starting DCVC treatment and shows the direct inhibition of caspase-3 like activity. The data are a summary of two separate experiments (n=2). (b) Lysates of LLC-PK1 cells exposed to 0 ± 2.5 mM DCVC in the presence of DPPD, as above, with and without 100 mM zVAD.fmk were immunoblotted with anti-PARP antibodies 24 h later. The arrows indicate the intact PARP (116 kD) and its signature fragments (85 kD); representative of results determined in three separate experiments (n=3). (c) LLC-PK1 cells were exposed to 2.0 mM DCVC in the presence of DPPD for 6 h and then returned to complete medium with or without 100 mM zVAD.fmk, zFA.fmk and zAAD.Clmk in the presence of DPPD. Cell lysate were prepared 24 h after starting the DCVC treatment and immunoblot analysis performed with anti-caspase-3 polyclonal antibody. The molecular weights indicate the intact caspase-3 (32 kD; marked Casp-3), the p19 fragment and the active p17 fragment. The data are a representative of three independent experiments (n=3)
Cell death in renal epithelial cells Y Zhan et al activity was detected. Cleavage of PARP to the 85 kd fragment, a signature of caspase 3 activation, was also blocked by zVAD.fmk (Figure 5b ). At the same time, 32 kDa procaspase-3 was hydrolyzed to a p19 fragment and then to active p17 (Figure 5c ). zVAD.fmk did not block the processing of the 32 kDa to p19, but did block further processing to p17. Interestingly, zAAD.Clmk, an inhibitor of the granzyme B-dependent activation pathway for caspase-3 activation (Antoku et al., 1997; Martin et al., 1996) , did not inhibit DCVC-induced cell death (data not shown) and had no eect on caspase-3 cleavage. The results implicate a caspase-3-like proteases in DCVCinduced apoptosis in LLC-PK1 cells. Treatment with zFA.fmk partially blocked DCVCinduced LDH release and increased the DNA content of apoptotic cells but did not prevent DNA fragmentation (Figures 1 and 4) . In addition, zFA.fmk increased the amount of the procaspase-3 fragments and the per cent present as p19 in DCVC treated cells (Figure 5b ). This suggests that blocking cathepsin activity delayed secondary necrosis and cell lysis, thus, p17 and p19 proteolytic fragments of caspase-3 accumulate in the apoptotic bodies (see Discussion). In addition, zFA.fmk may be delaying processing of the caspase-3 derived p19 to active p17.
Eect of bcl-2 expression on DCVC and cisplatin-induced apoptosis
Bcl-2 prevents release of cytochrome C from mitochondria preventing caspase-3 activation in some models of apoptosis (Yang et al., 1997; Green and Reed, 1998) . We determined if caspase-3 activation is inhibited by enforced bcl-2 expression in LLC-PK1 cells. Both control cells, which had been transfected with an empty vector and selected for G418 resistance (pkNeo cells), and two clones of cells overexpressing bcl-2 (pkBcl-2 cells; data not shown) were treated with DCVC and apoptosis was monitored quantitatively bȳ ow cytometry. The con¯uent cultures were largely in G0/G1 phase of the cell cycle. There was no dierence in the percentage of subG0/G1 apoptotic cells in pkNeo vs pkBcl-2 cells after DCVC treatment ( Figure  6 ). However, pkBcl-2 cells were signi®cantly less sensitive to cisplatin-induced apoptosis compared to pkNeo cells. Overexpression of bcl-2 also signi®cantly inhibited the increase in caspase-3 activity detected after cisplatin treatment (Figure 7) . But, there was only a modest and insigni®cant decrease in caspase-3 activity in DCVC treated pkBcl-2 vs pkNeo cells (Figure 7) . Thus, activation of caspase-3 by DCVC is largely independent of bcl-2 expression.
Discussion
The kidney is a target for toxic drugs, pollutants and industrial chemicals. Although apoptosis occurs during renal injury (Edelstein et al., 1997; Lieberthal and Levine, 1996) , little is known about the mechanism. In a previous investigation, we examined the role of caspases in cell detachment and loss of signaling through focal adhesion kinase in renal epithelial cells (van de Water et al., 1999) . In this study, we examined the role of caspases and bcl-2 in the killing of kidney cells by nephrotoxicants. Our studies suggest that caspases are essential proteases in apoptosis but not necrosis induced by cisplatin and DCVC in LLC-PK1 renal epithelial cells. Caspase-3 and PARP were cleaved indicative of caspase-3 activation and DEVDase activity was detected in apoptotic cells. Finally, the structure activity relationship for inhibition of Figure 6 Bcl-2 blocks cell death following cisplatin, but not DCVC. Two clones of LLC-PK1 cells that over express bcl-2 (pkBcl 6 and pkBcl 10) and two Neo clones (pkNeo1 and pkNeo 2) were treated with dierent concentrations of DCVC for 6 h (left panel) or with 100 mM cisplatin (right panel) for dierent times, as indicated, and returned to complete medium. Cell cycle analysis was performed 24 h after starting the DCVC or cisplatin treatment to estimate the per cent apoptotic cells (Sub G0/G1). Data from the two clones of pkNeo or pkBcl-2 cells were pooled and treated as a single observation; mean+s.d. of three separate experiments (n=3). Signi®cant dierences (P50.05) in cell death between the pkNeo and pkBcl-2 cells, within each concentration (DCVC) or treatment condition (cisplatin), were determined by Student's t-test. Signi®cant protection in pkBcl-2 vs pkNeo cells is marked with a double asterisk Figure 7 Bcl-2 blocks caspase-3 activation after cisplatin but not DCVC treatment. The same pkBcl-2 and pkNeo clones used in Figure 6 were treated EBSS alone, with 1.5 mM DCVC plus DPPD for 6 h or with 100 mM cisplatin for 4 h and then returned to complete medium. Cells treated with DCVC were in the presence of DPPD during the treatment and recovery periods. Cleavage of Ac-DEVD-pNA in cell lysates prepared from untreated and toxicant treated pkNeo and pkBcl-2 cells was determined after 24 h. Each data bar represents the mean+s.d. of data collected in three separate experiments (n=3). Signi®cant dierences (P50.05) between the pkNeo and pkBcl-2 clones were determined by a Student's t-test. Where a signi®cant dierence was detected, the means are marked with an asterisk (*, pkNeo and ** pkBcl-2)
Cell death in renal epithelial cells Y Zhan et al apoptosis by protease inhibitors was consistent with inhibition of caspase-3. However, unlike other models, DCVC-induced apoptosis, and to a large extent caspase-3 activation, were independent of bcl-2 expression despite the fact that a bcl-2-sensitive pathway to caspase-3 activation is operative when the cells were treated with cisplatin.
Caspase activation did not occur in cells treated with TFEC, which does not induce apoptosis, nor when DPPD was omitted during DCVC treatment, a condition that leads to necrosis (Zhan et al., 1997) . In addition, pharmacological agents that block necrosis did not block caspase-3 activation or apoptosis after DCVC (data not shown). Thus, DCVC induces apoptosis and necrosis by a common initiating events, metabolism by the b-lyase (Stevens et al., 1986; Zhan et al., 1997) , but, the pathways leading to caspase-3 activation and apoptosis diverges upstream from the perturbations that initiate necrosis. This interpretation is supported by the fact that necrosis caused by TFEC treatment, is linked to a similar set of biochemical perturbations to those that result in DCVC-induced necrosis, yet TFEC does not activate caspase-3 ( (Chen et al., 1990) and Table 1 ). Although the signals that activate cell death in this model are not clear at present, DNA damage may play a role since DCVC, but not TFEC, is genotoxic (Vamvakas et al., 1989) . In addition, loss of signaling through focal adhesion kinase may contribute to caspase activation (van de Water et al., 1999) and TFEC is less eective in causing cell detachment (van de Water et al., 1994) .
Cathepsins have also been implicated in apoptosis (Roberts et al., 1997; Moallem and Hales, 1995) . Cathepsin B is induced in prostate (Guenette et al., 1994) and mammary epithelia undergoing apoptosis (Simboli-Campbell et al., 1997) . Cathepsin B inhibitors prevent bile salt-induced apoptosis of hepatocytes (Roberts et al., 1997) . Releasing cathepsins induces apoptosis directly as does ectopic expression of cathepsin D (Brunk et al., 1997; Deiss et al., 1996) . Cyclophosphamide treatment induced cathepsin D and apoptosis in developing limbs (Moallem and Hales, 1995) . In addition, decreasing cathepsin D expression blocks apoptosis induced by Fas ligation or inteferon gamma (Deiss et al., 1996) . The potent cathepsin B inhibitor zFA.fmk but not the broader cathepsin inhibitors pepstatin A and E64 (Barrett et al., 1982; Lotem and Sachs, 1996) partially inhibited LDH leakage but did not block cell death. In addition, zFA.fmk treatment actually increased the DNA content and the amount of caspase-3 fragments in apoptotic cells. Thus, cathepsins may play a late role in apoptosis, perhaps in secondary necrosis, or as suggested (Gregoli and Bondurant, 1999) , in the processing of caspase-3 p19 to the active p17.
The bcl-2 data are interesting since activation of cmyc expression by DCVC is a component of the apoptotic pathway (Zhan et al., 1997) . Enforced activation of c-myc alone causes apoptosis and caspase-3 activation (Kayaga et al., 1997) which is blocked by bcl-2 expression in many cell types (Bissonnette et al., 1992; Fanidi et al., 1992; Wagner et al., 1993) . Ectopic expression of c-myc in mouse kidney in vivo (Trudel et al., 1997) and in LLC-PK1 cells (Zhan et al., 1997) results in apoptosis with accompanying caspase activation (Zhan and Stevens, unpublished results). However, bcl-2 does not block cmyc-induced apoptosis in mouse kidney in vivo (Trudel et al., 1997) nor in the present study despite the fact that c-myc signals apoptosis downstream of DCVC treatment (Zhan et al., 1997) . Thus, there may be apoptotic pathways in kidney epithelial cells that are linked to c-myc and caspase-3 activation but which are not bcl-2 dependent. We should point out that dierent pkBcl-2 clones show some variability in their response. For example, both clones used in this study had comparable Bcl-2 levels but there was a modest decrease in DNA ladder formation in one of the clones even though bcl-2 expression had no eect on apoptosis, as determined by cell cycle analysis, or caspase-3 activation in either clone. Regardless, the fact that cisplatin-induced apoptosis and caspase-3 activation were blocked in both clones argues that the pathway of DCVC-induced apoptosis is Bcl-2-independent. The granzyme B-dependent pathway for caspase, which may not be Bcl-2 sensitive (Darmon et al., 1996) is not involved in DCVC-induced apoptosis since granzyme B inhibitors had no eect.
In conclusion, apoptosis caused by treatment with the nephrotoxicant DCVC treatment involves caspase-3 activation. Although the signals that activate caspase-3 in kidney epithelial cells are still not clear, this is the ®rst study to demonstrate chemically induced apoptosis involving caspase-3 activation in a bcl-2 independent fashion. These ®ndings may shed new light on the mechanism of apoptosis induced by nephrotoxicants and on the role of c-myc activation in chemicallyinduced apoptosis. If caspase-3 activation is crucial in kidney damage, then inhibition of caspase-3 may provide a new therapeutic target in treating kidney diseases. In addition, bcl-2 dependent and independent pathways are induced by dierent pathways in the same cell line, LLC-PK1 cells, indicates that this is a novel model in which to study the mechanisms of caspase-3 activation in kidney epithelial cells.
Materials and methods
Materials
Fetal bovine serum and Dulbecco's Modi®ed Eagle's Medium (DMEM) were purchased from Life Technologies, Inc. (Grand Island, NY, USA). LLC-PK1 cells were obtained from American Type Culture Collection (Rockville, MD, USA) at passage 195 and used from passages 204 ± 214. DCVC and TFEC were synthesized as before (Zhan et al., 1997) . N,N'-Diphenyl-p-phenylenediamine (DPPD) was obtained from Kodak. Carbobenzoxy (z) and¯uorinated (fmk) or chlorinated (Clmk) methyl ketone protease inhibitors (zVAD.fmk, zAAD.Clmk and zFA.fmk) and anti-PARP antibody were obtained from Enzyme System Products (Dublin, CA, USA). Polyclonal antibody against the p17 fragment of caspase-3 was a generous gift of Dr D Nicholson (Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, Quebec). Acetyl-Asp-Glu-Val-Asp-p-nitroanilide (Ac-DEVD-pNA) and Acetyl-Tyr-Val-Ala-Asp-p-nitroanilide (Ac-YVAD-pNA) were purchased from California Peptide Research, Inc. (Napa, CA, USA). All other chemicals were obtained from commercial sources unless indicated otherwise.
Cell culture and treatment with chemicals
Methods for culture of LLC-PK1 cells have been described; con¯uent monolayers were used for all experiments (Zhan et al., 1997) . Cells were treated with 100 mM cisplatin in Earle's balanced salt solution (EBSS) for 2, 4 or 6 h and returned to complete medium. In the presence of the antioxidant DPPD, DCVC-induced cell death changes from necrosis to apoptosis (van de Water et al., 1996; Zhan et al., 1997) . Therefore, apoptosis was initiated with DCVC in EBSS the presence of 20 mM DPPD and in the absence of DPPD when necrosis was studied (Zhan et al., 1997) . After treatment, cells were returned to DMEM with 10% serum (complete medium) for the duration of the experiment. Since cells show dierential sensitivity to DCVC and TFEC in the presence and absence of DPPD, when the two pathways were compared (Table 1) cells were treated as follows: 0.5 mM TFEC+DPPD, 0.25 mM TFEC7DPPD, 1.5 mM DCVC+DPPD and 0.5 mM DCVC7DPPD to induce comparable percentages of cell death. TFEC does not induce apoptosis with or without DPPD (Zhan et al., 1997) . DPPD was not added during or after cisplatin treatment since it kills cells by apoptosis regardless (data not shown). Unless indicated, cell death was determined 24 h after starting treatment. Protease inhibitors were added only after removing the toxicant to exclude possible interference with uptake or activation.
Analysis of cell death
Total cell death was determined by leakage of lactate dehydrogenase (LDH) which can also be an index of necrosis. However, during apoptosis, LDH release results from secondary necrosis (Majno and Joris, 1995), as described in LLC-PK1 cells (Zhan et al., 1997) and is a reliable measure of cell death and apoptosis if used in conjunction with other markers. DNA ladders, nuclear fragmentation and¯ow cytometry were used to detect apoptotic cells. Low molecular weight`ladders' were extracted from cell lysates and measured as described (Zhan et al., 1997) . Analysis of the DNA content by¯ow cytometry of propidium iodide stained cells was also used to quantify apoptosis using a Coulter EPICS XL¯ow cytometer. Floating cells were collected and then combined with attached cells collected by trypsinization. Cells with a DNA content less than the G0/G1 population (apoptotic cells) were quantitated using the Multicycle application of the Multiplus software (Phoenix Flow Systems, Tucson, AZ, USA). In the absence of DPPD, LLC-PK1 cells die by necrosis (Zhan et al., 1997) . Ruptured necrotic cells are digested by trypsin and are not scored by¯ow cytometry, thus, the method is speci®c for apoptosis. In general, LDH release and¯ow cytometry yielded similar results within an experiment. However, the concentration dependence for DCVC cell death is very steep; maximal cell killing occurs within a range from 0.5 ± 2 mM. Therefore variations in the cell death were observed between experiments. Thus, repeat experiments were clustered to synchronize conditions and reduce variability within a protocol. Nonetheless, dierences in the amount of cell death were seen when protocols were separated in time (compare Figure 3 with Figure 6 for example).
Protease assays
Cell lysates were prepared as described with minor modi®cation (Datta et al., 1997; Emoto et al., 1995) . After centrifugation for 5 min at 14 000 r.p.m. (48C) the protein concentration in the supernatant was determined using the Bio-Rad Protein Assay. Protease assays were performed in 96-well plates in 178 ml of reaction buer containing 100 mM HEPES, (pH 7.5), 20% v/v glycerol, 5 mM dithiothreitol and 0.5 mM EDTA to which 2 ml of 10 mM Ac-DEVD.pNA or Ac-YVAD.pNA were added as substrates for caspase-3 or caspase-1, respectively, and 20 ml of cell lysate containing 50 mg of protein. After 1 h at 308C the p-nitroanaline release was monitored at 405 nm. pNitroanaline release was calculated from a standard curve and expressed as pmol/mg protein/min. Cleavage of PARP or caspase-3 was determined by immunoblotting using standard techniques and the Enhanced Chemiluminescence System (Amersham).
Statistical analyses
When two means were compared, signi®cant dierences (p50.05) were determined by a one tailed Student's t-test; signi®cant dierences are noted by asterisks. When more than two means were compared, signi®cant dierences were determined by a one-way analysis of variance (ANOVA) followed by multiple comparisons using the Student-Newman-Keul's test; signi®cant dierences are noted in the ®gures by letter designations or asterisks. When letter designations are shown, means with one letter designation are signi®cantly dierent from means with another letter designation. Thus, a mean marked A is signi®cantly dierent from a mean marked B, while a mean marked AB is not dierent from either A or B.
Abbreviations DCVC, S-(1,2-dichlorovinyl)-L-cysteine; DMEM, Dulbecco's modi®ed Eagles's medium; DPPD, N,N'-phenyl-pphenylenediamine; LDH, lactate dehydrogenase; PARP, poly(ADP-ribose) polymerase; pkBcl-2, cells transfected with a bcl-2 expression vector and selected for neomycin resistance; pkNEO, cells transfected with a neomycin resistance marker only; TFEC, S-(1,1,2,2-tetrafluoroethyl)-L-cysteine.
